Berntorp E, Boulyjenkov V, Brettler D, Chandy M, Jones P, Lee C, et al. Modern treatment of haemophilia. Bull World Health Organ. 1995;73:691–701.
Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, et al. Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia. 2014;20:322–5.
Richards M, Williams M, Chalmers E, Liesne R, Collins P, Vidler V, et al. Paediatric Working Party of the United Kingdom Haemophilia Doctors’ Organisation. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149:498–507.
Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935–9.
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–44.
Giangrande P, Calizzani G, Menichini I, Candura F, Mannucci PM, Makris M. The European standards of Haemophilia Centres. Blood Transfus. 2014;12 Suppl 3:S525–30.
Clausen N, Petrini P, Claeyssens-Donadel S, Gouw SC, Liesner R, PedNet, Research of Determinants of Inhibitor development (RODIN) Study Group. Similar bleeding phenotype in young children with haemophilia A or B: a cohort study. Haemophilia. 2014;20:747–55.
Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol. 1999;105:1109–13.
Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group, et al. Tailored prophylaxis in severe haemophilia A: interim results from the first 5 year of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006;4:1228–36.
Kraft J, Blanchette V, Babyn P, Feldman B, Cloutier S, Israels S, Pai M, et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia A treated with tailored primary prophylaxis in Canada. J Thromb Haemost. 2012;10:2494–502.
Stieltjes N, Calvez T, Demiguel V, Torchet MF, Briquel ME, Fressinaud E, Claeyssens S, et al. French ICH Study Group. Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death. Haemophilia. 2005;11:452–8.
Traivaree C, Blanchette V, Armstrong D, Floros G, Stain AM, Carcao MD. Intracranial bleeding in haemophilia beyond the neonatal period--the role of CT imaging in suspected intracranial bleeding. Haemophilia. 2007;13:552–9.
Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140:378–84.
Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol. 2011;152:211–6.
Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia. 1998;4:413–7.
Skinner MW. WFH: Closing the global gap – achieving optimal care. Haemophilia. 2012;18 Suppl 4:1–12.
Fischer K, Steen Carlsson K, Petrini P, Holmström M, Ljung R, van den Berg HM, Berntorp E. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122:1129–36.
Soreff J, Blombäck M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand. 1980;69:667–73.
Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res. 1980;149:153–9.
Lundin B, Ljung R, Pettersson H, European Paediatric Network for Haemophilia Management (PEDNET). MRI scores of ankle joints in children with haemophilia--comparison with clinical data. Haemophilia. 2005;11:116–22.
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, et al. rAHF–PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7:413–20.
Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010;8:269–75.
Powell J, Shapiro A, Ragni M, Negrier C, Windyga J, Ozelo M, et al. Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. Br J Haematol. 2015;168:113–23.
Morado M, Villar A, Jiménez Yuste V, Quintana M, Hernandez NF. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia. 2005;11:79–83.
Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study. Br J Haematol. 2005;130:422–7.
Gouw SC, van der Bom JG, van den Berg MH. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–54.
Kurnik K, Auerswald G, Kreuz W. Inhibitors and prophylaxis in paediatric haemophilia patients: Focus on the German experience. Thromb Res. 2014;134(S1):S27–32.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, PedNet, Research Of Determinants of INhibitor development (RODIN) Study Group, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121:4046–55.
Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119–27.
Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol. 2012;88:329–35.
Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med. 1994;236:391–9.
Oldenburg J, Albert T. Novel products for haemostasis - current status. Haemophilia. 2014;20 Suppl 4:23–8.
Powell JS, Pasi KJ, Ragni MV, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013;369:2313–23.
Santagostino E, Martinowitz U, Lissitchkov T, et al. Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016;127(14):1761–9.
Collins PW, Young G, Knobe K, et al. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124:3880–6.
Young G, Mahlangu JN. Extended half-life clotting factor concentrates: results from published clinical trials. Haemophilia. 2016;22 Suppl 5:25–30.
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, Cortesi P, Jo H, Kavakli K, Lassila R, Morfini M, Négrier C, Rocino A, Schramm W, Serban M, Uscatescu MV, Windyga J, Zülfikar B, Mantovani L. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365:1684–92.
Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014;20:65–72.
Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–13.
López-Fernández MF, Altisent Roca C, Álvarez-Román MT, Canaro Hirnyk MI, Mingot-Castellano ME, Jiménez-Yuste V, Cid Haro AR, Pérez-Garrido R, Sedano Balbas C. Spanish Consensus Guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors. Thromb Haemost. 2016;115:872–95.
Ljung R, Gretenkort AN. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol. 2015;169:777–86.